Sequana Medical is a Swiss medical device company specializing in the development of innovative implantable pump systems to manage fluid balance within the body. The company primarily serves patients suffering from diuretic-resistant fluid overload conditions such as liver disease, malignant ascites, and heart failure. Operating in the medical device market, Sequana Medical's core product, the alfapump, is a breakthrough system designed for the automatic and continual removal of ascites, which is the accumulation of fluid in the abdomen. The alfapump has received CE Mark approval for the treatment of liver refractory ascites and malignant ascites, and is being developed for use in patients with volume overload due to heart failure. Sequana Medical generates revenue through the sale of its alfapump systems and related services. The company has built a strong body of clinical evidence demonstrating the safety, efficacy, and quality of life benefits of its products in over 800 implanted patients.

Keywords: implantable pump, fluid balance, liver disease, malignant ascites, heart failure, diuretic-resistant, alfapump, CE Mark, medical device, clinical evidence.